Analyst Upgrades: Intel, GoPro, Galmed Pharma

Analysts upwardly revised their ratings on Intel Corporation (INTC), GoPro Inc (GPRO), and Galmed Pharmaceuticals Ltd (GLMD)

Apr 15, 2015 at 9:26 AM
facebook X logo linkedin

Analysts are weighing in today on tech giant Intel Corporation (NASDAQ:INTC), mountable camera maker GoPro Inc (NASDAQ:GPRO), and biopharmaceutical firm Galmed Pharmaceuticals Ltd (NASDAQ:GLMD). Here's a quick roundup of today's bullish brokerage notes on INTC, GPRO, and GLMD.

  • After last night reporting first-quarter profits roughly in-line with expectations, INTC is 3% higher ahead of the open. The stock had been picking up steam going into the report, adding 7.4% since hitting a 2015 low of $29.31 on March 26 to settle at $31.49 yesterday. Intel Corporation could see additional gains, too, if it can sustain today's rally. Of the 29 brokerage firms with coverage on the shares, 13 deem them a "hold" or worse. Also, INTC is approaching its average 12-month price target of $34.61 -- a level it already topped in 2015. Don't be surprised to see analyst upgrades and/or price-target hikes boost the shares. In fact, just this morning, the stock saw no fewer than nine brokerage firms raise their price targets, with RBC as the most ambitious, setting a target of $40. Also, RBC and Wedbush each upgraded INTC to "outperform" from the equivalent of "neutral." Three other brokerage firms, however, cut their price targets on the security.

  • GPRO is working to gain back some of its nearly 30% year-to-date drop, with shares pointed 2.5% higher in electronic trading. The surge comes after Piper Jaffray upgraded the stock to "overweight," citing a strong adoption rate among teens. Even so, with GoPro Inc closing at $44.48 yesterday, it remains 30% below its consensus 12-month price target of $63.23, leaving the shares vulnerable to price-target cuts. Options bulls have remained stubborn during the stock's decline, as calls have been in high demand. In fact, 2.78 calls have been bought to open for every put during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). A capitulation among these optimists could result in headwinds.

  • Roth Capital started coverage on GLMD with a "buy" rating and $20 price target -- more than double its close at $8.78 yesterday. The shares have already added more than 50% in 2015, outpacing the S&P 500 Index (SPX) by 27.5 percentage points during the past two months. Roth Capital's price target isn't too shocking when looking at Galmed Pharmaceuticals Ltd's average 12-month price target, which stands at $24 -- territory never before explored.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI